0R34 Stock Chart & Stats
$234.83
-$3.20(-2.19%)
At close: 4:00 PM EST
$234.83
-$3.20(-2.19%)
Day’s Range― - ―
52-Week Range$154.82 - $269.50
Previous CloseN/A
Volume15.31K
Average Volume (3M)14.19K
Market Cap
$623.71B
Enterprise Value$597.07B
Total Cash (Recent Filing)$22.05B
Total Debt (Recent Filing)$54.99B
Price to Earnings (P/E)29.6
Beta0.60
Next Earnings
Jul 15, 2026EPS Estimate
2.86Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.67
Shares Outstanding2,407,217,000
10 Day Avg. Volume11,104
30 Day Avg. Volume14,190
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)6.18
Price to Sales (P/S)5.35
P/FCF Ratio25.59
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue6.20
Enterprise Value/Gross Profit8.96
Enterprise Value/Ebitda17.83
Forecast
1Y Price Target
$268.07Price Target Upside14.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16
EPS Forecast (FY)11.59
Revenue Forecast (FY)$101.04B
Bulls Say, Bears Say
Bulls Say
Durable Revenue GrowthJohnson & Johnson has demonstrated steady top-line expansion over multiple years, reflecting broad-based demand across Pharmaceuticals and MedTech. This multi-year revenue trend indicates a resilient commercial footprint and diversified product mix that supports durable growth absent short-term market moves.
High, Sustainable ProfitabilityConsistently elevated margins across the enterprise point to structural pricing power, efficient scale in manufacturing and R&D, and a portfolio biased to higher-margin pharmaceuticals. These margin levels underpin strong earnings power and long-term capacity to fund innovation and shareholder returns.
Strong Cash Generation & Capital ReturnsLarge absolute free cash flow and a sizable cash balance enable sustained dividend growth, reinvestment and capex plans (including a multi‑year U.S. manufacturing/R&D program). Reliable cash generation supports capital allocation flexibility and long-term strategic investments.
Bears Say
Material STELARA ErosionA very large, rapid decline in a legacy blockbuster due to biosimilars and new-class adoption highlights structural vulnerability: loss of entrenched revenue can meaningfully depress growth and forces reliance on launches to replace material cash flows over multiple years.
Margin Deleverage From Sustained Launch InvestmentManagement is deploying heavier SG&A and launch spend to support new products, which materially compresses margins. If launches take longer to ramp or mix remains unfavorable, sustained investment intensity could keep margins below prior peaks and limit near-term cash conversion.
Weaker Cash-flow Momentum & Timing VolatilityWhile absolute cash generation is large, recent FCF decline and OCF being well below net income signal working-capital swings and timing effects. That reduces predictability of free cash flow, complicating durable planning for buybacks, dividends and capex absent execution improvement.
Johnson & Johnson News
0R34 FAQ
What was Johnson & Johnson’s price range in the past 12 months?
Johnson & Johnson lowest share price was $154.82 and its highest was $269.50 in the past 12 months.
What is Johnson & Johnson’s market cap?
Johnson & Johnson’s market cap is $623.71B.
When is Johnson & Johnson’s upcoming earnings report date?
Johnson & Johnson’s upcoming earnings report date is Jul 15, 2026 which is in 4 days.
How were Johnson & Johnson’s earnings last quarter?
Johnson & Johnson released its earnings results on Apr 14, 2026. The company reported $2.7 earnings per share for the quarter, beating the consensus estimate of $2.677 by $0.023.
Is Johnson & Johnson overvalued?
According to Wall Street analysts Johnson & Johnson’s price is currently Undervalued.
Does Johnson & Johnson pay dividends?
Johnson & Johnson does not currently pay dividends.
What is Johnson & Johnson’s EPS estimate?
Johnson & Johnson’s EPS estimate is 2.86.
How many shares outstanding does Johnson & Johnson have?
Johnson & Johnson has 2,407,217,000 shares outstanding.
What happened to Johnson & Johnson’s price movement after its last earnings report?
Johnson & Johnson reported an EPS of $2.7 in its last earnings report, beating expectations of $2.677. Following the earnings report the stock price went up 2.217%.
Which hedge fund is a major shareholder of Johnson & Johnson?
Currently, no hedge funds are holding shares in GB:0R34
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Johnson & Johnson Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$268.07 (14.16% Upside)
$268.07 (14.16% Upside)
Blogger Sentiment
Bullish
GB:0R34 Sentiment 70%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth $2.4M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
68.96%
12-Months-Change
Fundamentals
Return on Equity
26.26%
Trailing 12-Months
Asset Growth
3.73%
Trailing 12-Months
Company Description
Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
0R34 Company Deck
0R34 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a broadly positive commercial and pipeline story: strong top-line operational growth, multiple high-growth products (DARZALEX, CARVYKTI, TECVAYLI, TALVEY, RYBREVANT, TREMFYA) and successful new launches (ICOTYDE, INLEXZO) with raised full‑year guidance and clear long‑term targets (line of sight to double‑digit growth by decade end). Offsetting these positives were significant short‑term headwinds—most notably a steep STELARA decline, GAAP EPS volatility driven by prior-year one‑time items, margin deleverage from heavier launch investments and a soft Q1 free cash flow run‑rate. Management emphasized confidence in recovery/acceleration through the year, substantial R&D and manufacturing investments, and multiple upcoming catalysts, leading to an overall constructive outlook despite near‑term profitability and comparability pressures.View all GB:0R34 earnings summaries0R34 Sales Breakdown
64.12% Innovative Medicine
35.88% MedTech
0R34 Stock 12 Month Forecast
Average Price Target
$268.07
▲(14.16% Upside)
Technical Analysis
Options Prices
Currently, No data available
---